Format

Send to

Choose Destination
See comment in PubMed Commons below
Virol J. 2009 Dec 21;6:224. doi: 10.1186/1743-422X-6-224.

Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein.

Author information

1
Cytos Biotechnology AG, Wagistrasse 25, CH-8952 Schlieren, Switzerland. roger.beerli@cytos.com

Abstract

Influenza virus infection is a prevalent disease in humans. Antibodies against hemagglutinin have been shown to prevent infection and hence hemagglutinin is the major constituent of current vaccines. Antibodies directed against the highly conserved extracellular domain of M2 have also been shown to mediate protection against Influenza A infection in various animal models. Active vaccination is generally considered the best approach to combat viral diseases. However, passive immunization is an attractive alternative, particularly in acutely exposed or immune compromized individuals, young children and the elderly. We recently described a novel method for the rapid isolation of natural human antibodies by mammalian cell display. Here we used this approach to isolate human monoclonal antibodies directed against the highly conserved extracellular domain of the Influenza A M2 protein. The identified antibodies bound M2 peptide with high affinities, recognized native cell-surface expressed M2 and protected mice from a lethal influenza virus challenge. Moreover, therapeutic treatment up to 2 days after infection was effective, suggesting that M2-specific monoclonals have a great potential as immunotherapeutic agents against Influenza infection.

PMID:
20025741
PMCID:
PMC2804611
DOI:
10.1186/1743-422X-6-224
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center